news
Scientists find a cellular process that stops cancer before it starts
Salk research shows that cellular recycling process, thought to fuel cancer's growth, can actually prevent it...
List view / Grid view
Molecular Targets
news
‘Hidden pocket’ could be targeted to treat strokes
Researchers have identified a tiny hidden pocket on the NMDA receptor that could be targeted to treat strokes and seizures...
news
Drug sponge could minimise effects of cancer therapy
A drug 'sponge' could be the future method of soaking up excess drugs within the body after cancer treatments such as chemotherapy to prevent side effects...
article
New frontiers in G protein-coupled receptor drug discovery
G protein-coupled receptors (GPCRs) are seven transmembrane spanning proteins that mediate the physiological responses to a broad array of stimuli, including photons, biogenic amines, peptides and large proteins. They represent the target of approximately one-third of all approved drugs,1 yet paradoxically remain a relatively under-exploited protein class.
article
Expert view: Tackling drug discovery inefficiencies requires diverse libraries, technologies with broader applicability and actionable insights
Inefficiencies in drug discovery are hard to ignore when despite ever-increasing investment in pharmaceutical research and development, the number of new drugs approved by the US Food and Drug Administration (FDA) remains low.
whitepaper
Application note: A complete next-generation sequencing workflow for circulating cell-free DNA isolation and analysis
Circulating cell-free DNA (cfDNA) has been shown to have potential as a noninvasive substrate for the detection and monitoring of tumour cells. As circulating tumour DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection.
news
Molecular Devices introduces enterprise-level SoftMax Pro 7.1 GxP Software
Molecular Devices announced the launch of the new SoftMax® Pro 7.1 GxP Software with complete validation tools which achieves full FDA 21 CFR Part 11 compliance in GMP/GLP labs...
webinar
Harmonising drug-target binding data analytics on a single platform
6 November 2018 | By PerkinElmer
This webinar outlined the fundamentals of a design process where an experimental analytics data workflow is being integrated into a more seamlessly interactive platform...
webinar
Integrated fragment-based approach reveals enzymatic inhibitors with potential therapeutic application
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...
news
Immunotherapy targeting blood protein fibrin
Targeting the fibrin protein could ensure that fibrin leaking through the blood-brain barrier does not cause inflammation or disease in the brain...
news
Laser-capture RNA seq technique connects Parkinson’s and psychiatric diseases
A comprehensive study reveals an expanding universe of 'darkest of the dark matter' RNAs in dopamine-producing cells in our brains...
news
Detecting epigenetic signature may help people stay ahead of IBD
Researchers have reported finding on an epigenetic signature in patient cells that appears to predict inflammation risk in Crohn's disease...
article
Pharmacological targeting of mitochondrial dysfunction in Parkinson’s disease: approaches and perspectives
Mitochondrial dysfunction has been widely implicated in the neuronal degeneration in Parkinson’s disease (PD). Mitochondria-targeted protective compounds that prevent or minimise a wide range of mitochondrial defects constitute potential therapeutic strategies in the prevention and treatment of neuronal degeneration in PD.
article
Synthetic biology in drug discovery
Synthetic biology is broadly defined as the design and construction of novel artificial biological pathways, organisms or devices; or the redesign of existing natural biological systems.1 It brings together a range of disciplines and skills, from biology and chemistry to computing, bioinformatics and engineering.
article
Using bioactivity profiling to support the progression of phenotypic hits
This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.
